Skip to main content
Neurology logoLink to Neurology
. 2018 Sep 18;91(12):572–573. doi: 10.1212/WNL.0000000000006213

The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab

Aravindhan Baheerathan 1,*,, Cillian McNamara 1,*, Sabrina Kalam 1, Neil Rane 1, Tara D Barwick 1, Helen Grote 1, Richard Nicholas 1
PMCID: PMC6161558  PMID: 30224501

A 57-year-old woman with highly active relapsing-remitting multiple sclerosis (MS) treated with natalizumab developed dysarthria and right-sided hemiparesis. MRI demonstrated T2 hyperintensity (figure, A). CSF JC virus DNA titers were >1.1 M and progressive multifocal leukoencephalopathy (PML) was diagnosed. Natalizumab treatment was withdrawn.

Figure. T2-weighted MRI, T1-weighted contrast-enhanced image, and FDG-PET image.

Figure

(A, arrow) T2-weighted image shows right peridentate and middle cerebellar peduncle (MCP) hyperintensity consistent with progressive multifocal leukoencephalopathy (PML). Follow-up revealed florid T2 hyperintensity in cerebellum and brainstem (B, arrow), with enhancement (C). FDG-PET shows right cerebellar hypometabolism (D, black arrow) at original PML site and hypermetabolism (D, white arrows) in pons and left MCP consistent with PML–immune reconstitution inflammatory syndrome.

Four weeks later, bulbar weakness and left-sided hemiparesis developed despite falling JC virus titers. Repeat MRI raised the possibility of either deteriorating PML or PML–immune reconstitution inflammatory syndrome (IRIS) (figure, B and C). FDG-PET confirmed relative hypometabolism at the original site of PML and hypermetabolism in the left pons and middle cerebellar peduncle (figure, D), suggestive of PML-IRIS. Prednisolone was commenced with consequent disease stabilization.

Early treatment with steroids can be critical in blunting inflammation in PML-IRIS; however, their use may be associated with reduced JC virus clearance and subsequent exacerbation of PML. It can be challenging on MRI to distinguish among PML, PML-IRIS, and new MS activity. Thus, FDG-PET, in cases where there is doubt, can provide information to guide therapeutic decisions in this complex clinical context.

Author contributions

A.B.: wrote initial manuscript, subsequent editing and drafting. C.M.: selected images, figure legends, subsequent editing and drafting of manuscript. S.K.: reviewed initial manuscript, formatting and subsequent editing. N.R.: reviewed images and figure legends (MRI). T.D.B.: reviewed images and figure legends (nuclear medicine). H.G.: reviewed manuscript, involved in editing, drafting, and formatting. R.N.: overall manuscript review and senior author, primary supervisor of paper, final editing.

Study funding

No targeted funding reported.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.


Articles from Neurology are provided here courtesy of American Academy of Neurology

RESOURCES